Cardiovascular Outcomes Associated With Gonadotropin-Releasing Hormone Antagonists vs GonadotropinReleasing Hormone Agonists for Prostate Cancer Treatment: A MetaAnalysis of Randomized Controlled Trials

被引：0
|
作者：
Jaiswal, Vikash
Jaiswal, Akash
Saleeb, Marina
Jha, Mayank
Hanif, Muhammad
Kalra, Kriti
Evbayekha, Endurance O.
Agrawal, Vibhor
Ang, Song Peng
Zacks, Jerome S.
机构：
来源：
CIRCULATION | 2023年 / 148卷
关键词：
Cardiovascular Risk; Estrogen; Outcomes; Cardio-oncology;
D O I：
10.1161/circ.148.suppl_1.12107
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
A12107
引用
收藏
页数：3
相关论文
共 50 条
  • [21] Risk of cardiovascular disease following gonadotropin-releasing hormone agonists vs antagonists in prostate cancer: Real-world evidence from five databases
    George, Gincy
    Garmo, Hans
    Scailteux, Lucie-Marie
    Balusson, Frederic
    De Coster, Greet
    De Schutter, Harlinde
    Kuiper, Josephina G.
    Oger, Emmanuel
    Verbeeck, Julie
    Van Hemelrijck, Mieke
    INTERNATIONAL JOURNAL OF CANCER, 2021, 148 (09) : 2203 - 2211
  • [22] Gonadotropin-releasing hormone antagonist associated with lower cardiovascular risk compared with gonadotropin-releasing hormone agonist in prostate cancer: A nationwide cohort and in vitro study
    Chen, Dong-Yi
    Su, Po-Jung
    See, Lai-Chu
    Liu, Jia-Rou
    Chuang, Cheng-Keng
    Pang, See-Tong
    Tseng, Chi-Nan
    Chen, Shao-Wei
    Hsieh, I-Chang
    Chu, Pao-Hsien
    Lin, Yung-Chang
    Hsu, Cheng-Lung
    Chang, John Wen-Cheng
    Lin, Miao-Sui
    Pang, Jong-Hwei S.
    Hsieh, Ming-Jer
    Huang, Wen-Kuan
    PROSTATE, 2021, 81 (12): : 902 - 912
  • [23] Increasing use of gonadotropin-releasing hormone agonists for the treatment of localized prostate carcinoma
    Shahinian, VB
    Kuo, YF
    Freeman, JL
    Orihuela, E
    Goodwin, JS
    CANCER, 2005, 103 (08) : 1615 - 1624
  • [24] Bone loss in men with prostate cancer treated with gonadotropin-releasing hormone agonists
    Stoch, SA
    Parker, RA
    Chen, LP
    Bubley, G
    Ko, YJ
    Vincelette, A
    Greenspan, SL
    JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM, 2001, 86 (06): : 2787 - 2791
  • [25] Gonadotropin-releasing hormone agonists in prostate cancer: A comparative review of efficacy and safety
    Raja, T.
    Sud, Rahul
    Addla, Sanjai
    Sarkar, Kalyan K.
    Sridhar, P. S.
    Talreja, Vikas
    Jain, Minish
    Patil, Ketaki
    INDIAN JOURNAL OF CANCER, 2022, 59 : S142 - S159
  • [26] Gonadotropin-releasing Hormone Agonists and Acute Kidney Injury in Patients with Prostate Cancer
    Gandaglia, Giorgio
    Sun, Maxine
    Huc, Jim C.
    Novara, Giacomo
    Choueiri, Toni K.
    Nguyen, Paul L.
    Schiffmann, Jonas
    Graefen, Markus
    Shariat, Shahrokh F.
    Abdollah, Firas
    Briganti, Alberto
    Montorsi, Francesco
    Quoc-Dien Trinh
    Karakiewicz, Pierre I.
    EUROPEAN UROLOGY, 2014, 66 (06) : 1125 - 1132
  • [27] Gonadotropin-releasing hormone antagonists in the treatment of uterine leiomyoma
    Felberbaum, Ricardo E.
    Kuepker, Wolfgang
    Balogh, Balint
    Diedrich, Klaus
    GYNAKOLOGE, 2020, 53 (08): : 529 - 536
  • [28] Association of Gonadotropin-Releasing Hormone Agonists for Prostate Cancer With Cardiovascular Disease Risk and Hypertension in Men With Diabetes
    Lin, E.
    Garmo, Hans
    Van Hemelrijck, Mieke
    Zethelius, Bjorn
    Stattin, Par
    Hagstrom, Emil
    Adolfsson, Jan
    Crawley, Danielle
    JAMA NETWORK OPEN, 2022, 5 (08) : e2225600
  • [29] Gonadotropin-Releasing Hormone Agonists and the Risks of Type 2 Diabetes and Cardiovascular Disease in Men with Prostate Cancer
    Philip J. Saylor
    Nancy L. Keating
    Stephen J. Freedland
    Matthew R. Smith
    Drugs, 2011, 71 : 255 - 261
  • [30] Metabolic consequences of gonadotropin-releasing hormone agonists vs orchiectomy: a randomized clinical study
    Ostergren, Peter B.
    Kistorp, Caroline
    Fode, Mikkel
    Bennedbaek, Finn N.
    Faber, Jens
    Sonksen, Jens
    BJU INTERNATIONAL, 2019, 123 (04) : 602 - 611
12345